Somalogic Stock

Somalogic EBIT

Delisted

The EBIT of Somalogic (SLGC) as of Aug 14, 2026 is -152.53 M USD. In the previous year, EBIT was -175.76 M USD — a change of -13.22% (higher).

EBIT

-152.53 MUSD

YoY

-13.22%

Last updated:

In 2026, Somalogic's EBIT was -152.53 M USD, a -13.22% increase from the -175.76 M USD EBIT recorded in the previous year.

The Somalogic EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (undefined USD)
Date
EBIT (undefined USD)
Jan 1, 2023
0.00 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
0.00 base
Jan 1, 2027 (e)
0.00 base
Jan 1, 2028 (e)
0.00 base
Jan 1, 2029 (e)
0.00 base
Jan 1, 2030 (e)
0.00 base
YEAREBIT (undefined USD)
2030 est -
2029 est -
2028 est -
2027 est -
2026 est -
2025 est -
2024 est -
2023 -
2022 -
2021 -
2020 -
2019 -
Access this data via the Eulerpool API

Somalogic Revenue

Somalogic Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
81.72 M USD
-152.53 M USD
-130.38 M USD
Jan 1, 2024 (e)
98.63 M USD
-111.05 M USD
-97.51 M USD
Jan 1, 2025 (e)
116.77 M USD
-97.80 M USD
-81.88 M USD
Jan 1, 2026 (e)
143.16 M USD
-71.35 M USD
-97.59 M USD
Jan 1, 2027 (e)
170.24 M USD
-108.43 M USD
-86.33 M USD
Jan 1, 2028 (e)
205.33 M USD
-94.86 M USD
-71.31 M USD
Jan 1, 2029 (e)
245.51 M USD
-75.68 M USD
-50.67 M USD
Jan 1, 2030 (e)
292.94 M USD
-49.47 M USD
-28.15 M USD

Somalogic Margins

Somalogic stock margins

The Somalogic margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Somalogic. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Somalogic.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
41.15 %
-186.64 %
-159.54 %
Jan 1, 2024 (e)
41.15 %
-112.60 %
-98.87 %
Jan 1, 2025 (e)
41.15 %
-83.76 %
-70.12 %
Jan 1, 2026 (e)
41.15 %
-49.84 %
-68.17 %
Jan 1, 2027 (e)
41.15 %
-63.69 %
-50.71 %
Jan 1, 2028 (e)
41.15 %
-46.20 %
-34.73 %
Jan 1, 2029 (e)
41.15 %
-30.83 %
-20.64 %
Jan 1, 2030 (e)
41.15 %
-16.89 %
-9.61 %

Somalogic Stock analysis

What does Somalogic do? SomaLogic Inc is a diagnostic biotech company specializing in a new way of clinically diagnosing diseases. It was founded in 2000 by Larry Gold, a renowned researcher and pioneer in the field of molecular diagnostics. The idea behind Somalogic arose from the need to bridge the gap between clinical needs and conventional diagnostic methods. SomaLogic's business model can be described as a service provider and licensee. The company offers its customers a wide range of products and services, from technology development to clinical disease diagnosis. The model is based on Somalogic's unique ability to measure a large number of proteins simultaneously, thus creating a comprehensive picture of their biological activity. The spheres of Somalogic encompass three main areas: proteins, data, and biomedicine. The protein sphere refers to Somalogic's core competence in the field of proteomics. The company has developed a proprietary technology that allows for the measurement of up to 5000 proteins in a single sample. Somalogic's technology is based on a special sample format called "SOMAScan," which utilizes proprietary aptamer technology to achieve ultra-high protein molecular signature accuracy. Somalogic's data sphere is deeply rooted in both the protein sphere and the biomedicine sphere. The company has a proprietary database that encompasses thousands of proteins. This database is continuously updated and expanded to provide increasingly robust quantitative protein data. The database enables Somalogic to identify and validate specific protein signatures associated with diseases. Somalogic also utilizes machine learning and artificial intelligence tools to take the interpretation of this data to the next level. The biomedicine sphere of Somalogic is the area where the company brings its diagnostic and therapeutic developments to the market. Somalogic works closely with pharmaceutical companies and clinical laboratories to develop clinical diagnostic tests based on its proprietary technology. The company has generated valid clinical data on a range of diseases and demonstrated the ability to identify biomarkers specifically associated with certain diseases. In its business development, Somalogic has created and licensed a wide range of products. The company has successfully formed partnerships with a number of companies and institutions to provide both proteomics tools and services. Some notable examples include partnerships such as collaboration with Biogen in the development of diagnostic tools for multiple sclerosis and other neurological disorders. Another example of Somalogic's product range is the successful collaboration with the New York State Health Department, where the company used its technology to investigate the SARS-CoV-2 virus. In this context, Somalogic generated information about specific biomarkers for COVID-19 and other masked and bound viral diseases. SomaLogic has the potential to change the way diseases are diagnosed and therapeutically treated. The company is on a path to revolutionize the diagnostic capabilities of the healthcare system and leave its mark on the healthcare market. Somalogic is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Somalogic's EBIT

Somalogic's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Somalogic's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Somalogic's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Somalogic’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Somalogic stock

EBIT of Somalogic is -152.53 M USD in 2026.

EBIT of Somalogic changed from -175.76 M USD to -152.53 M USD, representing a -13.22% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT Somalogic since 2006 – with annual values, charts, and detailed analysis.

"Earnings before interest and taxes", abbreviated as EBIT, is also referred to as the operating result of a company. It is a key figure that allows the profit to be assessed over a specific period of time, usually a fiscal year. Taxes and interest are not deducted from EBIT, making it suitable for international comparisons of different companies.

Net income
+ Tax expense
+ Interest expense and other financial expenses
- Interest income and other financial income
= EBIT (operating profit)

EBIT's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT's Somalogic historically and in real time.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Somalogic

All Key Metrics — Somalogic